Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VENTURE STUDY EXPLORATORY ANALYSIS SHOWS VK2735 IMPROVED CARDIOMETABOLIC PARAMETERS AFTER 13 WEEKS; REDUCING PREDIABETES AND METABOLIC SYNDROME SAN DIEGO , NOV. 6, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT NEW CLINICAL DATA FROM THE COMPANY'S VK2735 OBESITY PROGRAM WERE HIGHLIGHTED IN A POSTER PRESENTATION AT OBESITYWEEK 2025, THE ANNUAL MEETING OF THE OBESITY SOCIETY. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS BEING DEVELOPED FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS.

VIKING THERAPEUTICS HIGHLIGHTS CLINICAL DATA FROM VK2735 OBESITY PROGRAM IN PRESENTATION AT OBESITYWEEK 2025

SAN DIEGO , NOV. 4, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAYANNOUNCED THAT THE COMPANY WILL PARTICIPATE AT TWO UPCOMING INVESTOR CONFERENCES. DETAILS OF THE COMPANY'S PARTICIPATION ARE AS FOLLOWS: STIFEL 2025 HEALTHCARE CONFERENCE DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AND IN INVESTOR MEETINGS CONFERENCE DATES: NOVEMBER 11-13, 2025 FIRESIDE CHAT TIME/DATE: 4:40  5:10 P.M.

VIKING THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

POSTER PRESENTATION ON VENTURE STUDY RESULTS EVALUATING IMPACT OF VK2735 ON PREDIABETES AND CARDIOMETABOLIC STATUS ADDITIONAL POSTER PRESENTATIONS SCHEDULED FOR AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025 SAN DIEGO , OCT. 29, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY'S VK2735 OBESITY PROGRAM WILL BE THE FOCUS OF TWO POSTER PRESENTATIONS AT OBESITYWEEK 2025, THE ANNUAL MEETING OF THE OBESITY SOCIETY. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS BEING DEVELOPED FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS.

VIKING THERAPEUTICS TO HIGHLIGHT CLINICAL DATA FROM VK2735 OBESITY PROGRAM IN PRESENTATIONS AT OBESITYWEEK 2025

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY PHASE 3 VANQUISH TRIALS FOR SUBCUTANEOUS VK2735 IN OBESITY PROCEEDING ON SCHEDULE VK2735 PHASE 1 MAINTENANCE DOSING STUDY UNDERWAY ADDITIONAL PHASE 2A VENTURE STUDY DATA TO BE PRESENTED ATOBESITYWEEK IN NOVEMBER STRONG QUARTER-END CASH POSITION OF $715 MILLION SAN DIEGO , OCT. 22, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

STUDY TO EXPLORE MAINTENANCE DOSING REGIMENS FOLLOWING INITIAL WEIGHT LOSS WITH VK2735 MONTHLY SUBCUTANEOUS, WEEKLY ORAL, AND DAILY ORAL REGIMENS TO BE EVALUATED SAN DIEGO , OCT. 21, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE INITIATION OF AN EXPLORATORY MAINTENANCE DOSING STUDY OF VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS SUCH AS OBESITY.

VIKING THERAPEUTICS ANNOUNCES INITIATION OF VK2735 MAINTENANCE DOSING CLINICAL TRIAL IN PATIENTS WITH OBESITY

CONFERENCE CALL SCHEDULED FOR WEDNESDAY, OCTOBER 22 AT 4:30 P.M. EASTERN TIME SAN DIEGO , OCT. 15, 2025 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 AFTER THE MARKET CLOSE ON WEDNESDAY, OCTOBER 22, 2025.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THIRD QUARTER 2025 ON OCTOBER 22, 2025

STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS, DEMONSTRATING STATISTICALLY SIGNIFICANT REDUCTIONS IN BODY WEIGHT WITH ONCE-DAILY VK2735 DOSING AS COMPARED TO PLACEBO UP TO 12.2% (26.6 LBS) MEAN WEIGHT LOSS OBSERVED AFTER 13 WEEKS OF VK2735 TREATMENT COMPARED WITH 1.3% (2.9 LBS) FOR PLACEBO EXPLORATORY ASSESSMENT OF LOW DOSE MAINTENANCE TREATMENT DEMONSTRATES POSITIVE PROOF OF CONCEPT VK2735 SHOWN TO BE SAFE AND WELL-TOLERATED IN 13-WEEK STUDY; 99% OF GI-SPECIFIC TREATMENT EMERGENT ADVERSE EVENTS CONSIDERED MILD OR MODERATE CONFERENCE CALL SCHEDULED FOR 8:00 A.M. ET TODAY SAN DIEGO , AUG. 19, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED POSITIVE TOP-LINE RESULTS FROM THE COMPANY'S PHASE 2 CLINICAL TRIAL OF THE ORAL TABLET FORMULATION OF VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS.

VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY PHASE 3 VANQUISH REGISTRATION TRIALS UNDERWAY FOR VK2735 IN OBESITY PHASE 2 VENTURE-ORAL DOSING TRIAL ENROLLMENT COMPLETED; TOP-LINE RESULTS EXPECTED 2H25 CONTINUED PROGRESS WITH AMYLIN PROGRAM; IND PLANNED 4Q25 STRONG QUARTER-END CASH POSITION OF $808 MILLION SAN DIEGO , JULY 23, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONFERENCE CALL SCHEDULED FOR WEDNESDAY, JULY 23 AT 4:30 P.M. EASTERN TIME   SAN DIEGO , JULY 16, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AFTER THE MARKET CLOSE ON WEDNESDAY, JULY 23, 2025.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR SECOND QUARTER 2025 ON JULY 23, 2025

VANQUISH-1 AND VANQUISH-2 STUDIES TO EVALUATE SUBCUTANEOUS VK2735 IN OBESE ADULTS WITH AND WITHOUT TYPE 2 DIABETES SAN DIEGO , JUNE 25, 2025 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE INITIATION OF THE VANQUISH PHASE 3 CLINICAL PROGRAM FOR VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF METABOLIC DISORDERS SUCH AS OBESITY.

Viking Therapeutics, Inc.

VKTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Viking Therapeutics, Inc.

VKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VKTX